Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis

P.C.M. van de Kerkhof; J. Berth‐Jones; Christopher Em Griffiths; P.V. Harrison; Herbert Hönigsmann; R. Marks; Rik Roelandts; Erwin Schöpf; C. Trompke

doi:10.1046/j.1365-2133.2002.04567.x

Abstract

1 min read

Tacalcitol ointment once daily was demonstrated to be efficacious, safe and well tolerated in the long-term control of plaque psoriasis in patients with up to 20% body surface involvement.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2025

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis over 5 years in patients living with obesity

Mark Lebwohl, Jerry Bagel, Ranga Gogineni, Christopher Em Griffiths

Article2003

Calcium homeostasis remains unaffected after 12 weeks' therapy with calcitriol 3 µg/g ointment; no correlation with extent of psoriasis

Juliet N. Barker, J. Berth‐Jones, Richard Groves, AD Omerod, E. Rizova, Christopher Em Griffiths

Article2025

Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis

Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, Tiago Torres, Zoran Popmihajlov, Ying-Ming Jou, Misti Linaberry, Carolin Daamen, Christopher Em Griffiths

Article2003

An International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque Psoriasis

Mark Lebwohl, Enno Christophers, Richard G. Langley, Jean Paul Ortonne, Janet L. Roberts, Christopher Em Griffiths

Article2003

Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis.

Jean-Paul Ortonne, Mark Lebwohl, Christopher Em Griffiths